Samsungbioepis Co,.Ltd
Samsung Bioepis Co., Ltd., a leading biopharmaceutical company headquartered in South Korea (KR), is renowned for its innovative approach in the biosimilars industry. Founded in 2012, the company has rapidly established itself as a key player in the global market, focusing on the development and commercialisation of high-quality biosimilars and biologics. With a strong presence in major operational regions including North America, Europe, and Asia, Samsung Bioepis offers a diverse portfolio of products that includes biosimilars for oncology and autoimmune diseases. Their commitment to rigorous research and development, combined with advanced manufacturing capabilities, sets them apart in a competitive landscape. Notable achievements include strategic partnerships with global pharmaceutical leaders, enhancing their market position and expanding access to affordable treatments. Samsung Bioepis continues to drive innovation, making significant contributions to the healthcare sector.
DitchCarbon Score
How does Samsungbioepis Co,.Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Samsungbioepis Co,.Ltd's score of 39 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Samsungbioepis Co,.Ltd's reported carbon emissions
In 2024, Samsungbioepis Co., Ltd. reported total carbon emissions of approximately 6,323,850 kg CO2e. This figure includes 1,220,325 kg CO2e from Scope 1 emissions and 5,103,525 kg CO2e from Scope 2 emissions. Additionally, the company disclosed Scope 3 emissions, which totalled approximately 37,809,000 kg CO2e from purchased goods and services, alongside significant contributions from other categories such as business travel (1,416,000 kg CO2e) and employee commute (1,073,000 kg CO2e). In terms of climate commitments, Samsungbioepis has set ambitious reduction targets, aiming to decrease GHG emissions by 32% from a 2022 baseline by the year 2030. This target applies to both Scope 1 and Scope 2 emissions, reflecting a strong commitment to mitigating their carbon footprint. The emissions data for 2023 showed a slight decrease, with total emissions reported at approximately 6,295,405 kg CO2e, comprising 1,209,479 kg CO2e from Scope 1 and 5,085,926 kg CO2e from Scope 2. The company has consistently reported emissions data, indicating a proactive approach to transparency and accountability in their environmental impact. It is important to note that emissions data for Samsungbioepis is cascaded from its parent company, Samsung Biologics Co., Ltd., which plays a significant role in the overall emissions profile and sustainability initiatives of the subsidiary.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 1,433,412 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,296,110 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Samsungbioepis Co,.Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
